Strongyloidiasis laboratory findings

Jump to navigation Jump to search

Strongyloidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Strongyloidiasis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Strongyloidiasis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Strongyloidiasis laboratory findings

CDC on Strongyloidiasis laboratory findings

Strongyloidiasis laboratory findings in the news

Blogs on Strongyloidiasis laboratory findings

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] : Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

The gold standard for the diagnosis of strongyloides is serial stool examination. Duodenal aspirate is more sensitive than stool examination, and duodenal biopsy may reveal parasites in the gastric crypts, in the duodenal glands, or eosinophilic infiltration in the lamina propria. In disseminated cases of strongyloidiasis, larvae can be detected in sputum by simple wet-mount in fluid from a bronchoalveolar lavage (BAL). Immunodiagnostic tests for strongyloidiasis are indicated when the infection is suspected and the organism cannot be demonstrated by duodenal aspiration, string tests, or by repeated examinations of stool. Enzyme immunoassay (EIA) is currently recommended because of its greater sensitivity (90%). Cross-reactions in patients with filariasis and some other nematode infections can occur. Antibody test results cannot be used to differentiate between the past and current infection.[1][2][3]

Laboratory Findings

Eosinophilia

Blood eosinophilia is generally present during the acute and chronic stages, but may be absent with dissemination.

Stool Samples

  • The gold standard for the diagnosis of strongyloides is serial stool examination.
  • The diagnosis rests on the microscopic identification of larvae (rhabditiform and occasionally filariform) in the stool or duodenal fluid.
  • Duodenal aspirate is more sensitive than stool examination, and duodenal biopsy may reveal parasites in the gastric crypts, in the duodenal glands, or eosinophilic infiltration in the lamina propria.
  • Specialized stool examinations include Baermann concentration, Horadi-Mori filter paper culture, quantitative acetate concentration technique, and nutrient agar plate cultures.
  • The stool can be examined in wet mounts:
    • Directly
    • After concentration (formalin-ethyl acetate)
    • After recovery of the larvae by the Baermann funnel technique
    • After culture by the Harada-Mori filter paper technique
    • After culturing in agar plates
  • The duodenal fluid can be examined using techniques such as the Enterotest string or duodenal aspiration.
  • In disseminated cases of strongyloidiasis, larvae can be detected in sputum by simple wet-mount in fluid from a bronchoalveolar lavage (BAL).
  • Diagnostic characteristics: length 200 to 250 µm (up to 380 µm); buccal cavity short, and prominent genital primordium.
A: Strongyloides stercoralis

A: The prominent genital primordium in the mid-section of the larva (black arrow) is readily evident. Note also the Entamoeba coli cyst (white arrow) near the posterior end of the larva. {{#ev:youtube|TSwN602mcn4}}

Antibody Detection

  • Immunodiagnostic tests for strongyloidiasis are indicated when the infection is suspected and the organism cannot be demonstrated by duodenal aspiration, string tests, or by repeated examinations of stool.
  • Antibody detection tests should use antigens derived from Strongyloides stercoralis filariform larvae for the highest sensitivity and specificity.
  • Although indirect fluorescent antibody (IFA) and indirect hemagglutination (IHA) tests have been used,
  • Immunocompromised persons with disseminated strongyloidiasis usually have detectable IgG antibodies despite their immunosuppression.
  • Cross-reactions in patients with filariasis and some other nematode infections can occur.
  • Antibody test results cannot be used to differentiate between the past and current infection.
  • A positive test warrants continuing efforts to establish a parasitological diagnosis followed by antihelminthic treatment.
  • Serologic monitoring may be useful in the follow-up of immunocompetent treated patients: antibody levels decrease markedly within 6 months after successful chemotherapy. [4]
  • More sensitive and specific serologic tests using recombinant antigens have been, and are being developed, and are available at specific laboratories.
  • An additional advantage to these serologic tests is that there is typically a significant drop in titer by 6 months after parasite eradication, which may make it possible to use these tests as a "test of cure."raph

References

  1. Mendes T, Minori K, Ueta M, Miguel DC, Allegretti SM (2017). "Strongyloidiasis Current Status with Emphasis in Diagnosis and Drug Research". J Parasitol Res. 2017: 5056314. doi:10.1155/2017/5056314. PMC 5292188. PMID 28210503.
  2. Beknazarova M, Whiley H, Ross K (2016). "Strongyloidiasis: A Disease of Socioeconomic Disadvantage". Int J Environ Res Public Health. 13 (5). doi:10.3390/ijerph13050517. PMC 4881142. PMID 27213420.
  3. Siddiqui AA, Berk SL (2001). "Diagnosis of Strongyloides stercoralis infection". Clin. Infect. Dis. 33 (7): 1040–7. doi:10.1086/322707. PMID 11528578.
  4. http://www.dpd.cdc.gov/dpdx/HTML/Strongyloidiasis.htm

Template:WH Template:WS